NBTXR 3

Drug Profile

NBTXR 3

Alternative Names: NBTXR-3; PEP-503

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Nanobiotix
  • Developer Nanobiotix; PharmaEngine
  • Class Antineoplastics; Radiosensitisers
  • Mechanism of Action Free radical stimulants; Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase II/III Soft tissue sarcoma
  • Phase I/II Head and neck cancer; Prostate cancer; Rectal cancer
  • Preclinical Hepatocellular carcinoma
  • No development reported Solid tumours

Most Recent Events

  • 23 Mar 2017 The Independent Data Monitoring Committee recommends the continuation of enrolment in the phase III trial on Soft tissue sarcoma
  • 14 Dec 2016 Preliminary efficacy and adverse events data from a phase I/II trial in Hepatocellular carcinoma released by Nanobiotix
  • 01 Nov 2016 Phase-I/II clinical trials in Prostate cancer in USA (Intratumoural) (NCT02805894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top